Free Trial

Bright Minds Biosciences (DRUG) Competitors

Bright Minds Biosciences logo
$63.14 -3.26 (-4.91%)
Closing price 10/17/2025 04:00 PM Eastern
Extended Trading
$64.63 +1.49 (+2.36%)
As of 10/17/2025 07:35 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

DRUG vs. GPCR, BHVN, STOK, ABCL, IMCR, VCEL, JANX, EWTX, RCUS, and HRMY

Should you be buying Bright Minds Biosciences stock or one of its competitors? The main competitors of Bright Minds Biosciences include Structure Therapeutics (GPCR), Biohaven (BHVN), Stoke Therapeutics (STOK), AbCellera Biologics (ABCL), Immunocore (IMCR), Vericel (VCEL), Janux Therapeutics (JANX), Edgewise Therapeutics (EWTX), Arcus Biosciences (RCUS), and Harmony Biosciences (HRMY). These companies are all part of the "pharmaceutical products" industry.

Bright Minds Biosciences vs. Its Competitors

Structure Therapeutics (NASDAQ:GPCR) and Bright Minds Biosciences (NASDAQ:DRUG) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, institutional ownership, profitability, media sentiment, analyst recommendations, earnings, valuation and risk.

Structure Therapeutics currently has a consensus price target of $68.67, suggesting a potential upside of 150.79%. Bright Minds Biosciences has a consensus price target of $81.00, suggesting a potential upside of 28.29%. Given Structure Therapeutics' higher possible upside, analysts clearly believe Structure Therapeutics is more favorable than Bright Minds Biosciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Structure Therapeutics
1 Sell rating(s)
0 Hold rating(s)
7 Buy rating(s)
1 Strong Buy rating(s)
2.89
Bright Minds Biosciences
0 Sell rating(s)
0 Hold rating(s)
8 Buy rating(s)
2 Strong Buy rating(s)
3.20

Structure Therapeutics has a beta of -1.65, suggesting that its share price is 265% less volatile than the S&P 500. Comparatively, Bright Minds Biosciences has a beta of -6.17, suggesting that its share price is 717% less volatile than the S&P 500.

Bright Minds Biosciences is trading at a lower price-to-earnings ratio than Structure Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Structure TherapeuticsN/AN/A-$122.53M-$1.05-26.08
Bright Minds BiosciencesN/AN/A-$2.06M-$0.93-67.89

Bright Minds Biosciences' return on equity of -20.96% beat Structure Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Structure TherapeuticsN/A -21.31% -20.34%
Bright Minds Biosciences N/A -20.96%-20.66%

In the previous week, Structure Therapeutics had 2 more articles in the media than Bright Minds Biosciences. MarketBeat recorded 4 mentions for Structure Therapeutics and 2 mentions for Bright Minds Biosciences. Bright Minds Biosciences' average media sentiment score of 1.29 beat Structure Therapeutics' score of 0.88 indicating that Bright Minds Biosciences is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Structure Therapeutics
2 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Bright Minds Biosciences
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

91.8% of Structure Therapeutics shares are owned by institutional investors. Comparatively, 40.5% of Bright Minds Biosciences shares are owned by institutional investors. 5.6% of Structure Therapeutics shares are owned by insiders. Comparatively, 42.7% of Bright Minds Biosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Bright Minds Biosciences beats Structure Therapeutics on 8 of the 14 factors compared between the two stocks.

Get Bright Minds Biosciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for DRUG and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DRUG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

DRUG vs. The Competition

MetricBright Minds BiosciencesMED IndustryMedical SectorNASDAQ Exchange
Market Cap$444.76M$3.45B$6.15B$10.56B
Dividend YieldN/A2.27%5.72%4.84%
P/E Ratio-67.898.2364.2322.90
Price / SalesN/A486.95612.78132.51
Price / CashN/A45.2825.8230.35
Price / Book68.6310.3812.226.58
Net Income-$2.06M-$52.81M$3.33B$276.84M
7 Day Performance-0.24%2.31%1.17%1.93%
1 Month Performance18.51%12.59%6.85%2.19%
1 Year Performance33.74%11.18%58.93%34.62%

Bright Minds Biosciences Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
DRUG
Bright Minds Biosciences
3.2063 of 5 stars
$63.14
-4.9%
$81.00
+28.3%
+33.7%$444.76MN/A-67.89N/APositive News
GPCR
Structure Therapeutics
3.2826 of 5 stars
$30.19
+0.4%
$68.67
+127.4%
-30.7%$1.73BN/A-28.75136News Coverage
BHVN
Biohaven
3.4683 of 5 stars
$15.29
-3.3%
$48.85
+219.6%
-69.8%$1.67BN/A-2.00239
STOK
Stoke Therapeutics
3.5362 of 5 stars
$30.34
+0.5%
$29.00
-4.4%
+157.9%$1.65B$36.56M35.69100
ABCL
AbCellera Biologics
2.4922 of 5 stars
$5.67
+2.5%
$8.00
+41.1%
+94.8%$1.65B$28.83M-10.31500
IMCR
Immunocore
1.9677 of 5 stars
$32.35
-0.2%
$56.89
+75.9%
-2.4%$1.63B$310.20M-80.88320
VCEL
Vericel
3.3348 of 5 stars
$33.49
+5.1%
$60.40
+80.4%
-15.2%$1.61B$237.22M279.11300News Coverage
Analyst Upgrade
Analyst Revision
JANX
Janux Therapeutics
2.2225 of 5 stars
$26.29
-0.8%
$78.31
+197.9%
-46.5%$1.59B$10.59M-14.6130News Coverage
EWTX
Edgewise Therapeutics
3.1341 of 5 stars
$14.71
-2.6%
$38.83
+164.0%
-57.7%$1.59BN/A-9.4960
RCUS
Arcus Biosciences
2.4046 of 5 stars
$16.64
+14.0%
$26.78
+61.0%
-10.6%$1.55B$258M-5.25500Gap Up
HRMY
Harmony Biosciences
4.7602 of 5 stars
$26.36
-0.7%
$46.11
+74.9%
-26.9%$1.53B$714.73M8.50200Analyst Forecast

Related Companies and Tools


This page (NASDAQ:DRUG) was last updated on 10/19/2025 by MarketBeat.com Staff
From Our Partners